Xin Ruobing, Xu Yiyang, Long Dianbo, Mao Guping, Liao Hongyi, Zhang Ziji, Kang Yan
Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Orthopedics and Traumatology, Guangzhou, China.
Front Pharmacol. 2022 Jun 6;13:911716. doi: 10.3389/fphar.2022.911716. eCollection 2022.
Mitochondrial dysfunction is related to the pathogenesis of osteoarthritis (OA); however, there are no effective drugs to treat OA for maintaining mitochondrial homeostasis. Studies have shown that mitochonic acid-5 (MA-5) has a protective effect against mitochondrial damage and plays a role in mitophagy. However, it is not clear whether MA-5 has a beneficial effect on inflammatory articular cartilage. Here, human OA cartilage was obtained from patients undergoing total joint replacement. Interleukin-1β (IL-1β) was used to stimulate chondrocytes and induce inflammatory injury. Cell Counting Kit-8, TUNEL, and flow cytometry assays were used to assess apoptosis. Gene expression was examined using quantitative reverse transcription-polymerase chain reaction. Mitochondrial function was evaluated using immunoblotting, mitochondrial membrane potential assay, JC-1 staining, and immunofluorescence analysis. Mitophagy was detected using immunoblotting and immunofluorescence. 3-(1H-1,2,3-triazol-4-yl) pyridine (3-TYP), a specific inhibitor of Sirtuin 3 (SIRT3), was used to block the SIRT3/Parkin pathway. Mitophagy in the cartilage sections was evaluated via immunohistochemistry. IL-1β was found to induce chondrocyte apoptosis by inhibiting SIRT3 expression and mitophagy. In addition, inflammatory damage reduced the mitochondrial membrane potential and promoted the production of intracellular reactive oxygen species (ROS), leading to increased mitochondrial division, mitochondrial fusion inhibition, and the consequent mitochondrial damage. In contrast, the MA-5 treatment inhibited excessive ROS production by upregulating mitophagy, maintaining the mitochondrial membrane potential, and reducing mitochondrial apoptosis. After chemically blocking SIRT3 with 3-TYP, Parkin-related mitophagy was also inhibited, an effect that was prevented by pretreatment of the chondrocytes with MA-5, thereby suggesting that SIRT3 is upstream of Parkin. Overall, MA-5 was found to enhance the activity of SIRT3, promote Parkin-dependent mitophagy, eliminate depolarized/damaged mitochondria in chondrocytes, and protect cartilage cells. In conclusion, MA-5 inhibits IL-1β-induced oxidative stress and protects chondrocytes by upregulating the SIRT3/Parkin-related autophagy signaling pathway.
线粒体功能障碍与骨关节炎(OA)的发病机制有关;然而,目前尚无有效药物可用于治疗OA以维持线粒体稳态。研究表明,线粒体酸-5(MA-5)对线粒体损伤具有保护作用,并在线粒体自噬中发挥作用。然而,MA-5对炎性关节软骨是否具有有益作用尚不清楚。在此,从接受全关节置换术的患者中获取人OA软骨。使用白细胞介素-1β(IL-1β)刺激软骨细胞并诱导炎性损伤。使用细胞计数试剂盒-8、TUNEL和流式细胞术检测评估细胞凋亡。使用定量逆转录-聚合酶链反应检测基因表达。使用免疫印迹、线粒体膜电位检测、JC-1染色和免疫荧光分析评估线粒体功能。使用免疫印迹和免疫荧光检测线粒体自噬。使用3-(1H-1,2,3-三唑-4-基)吡啶(3-TYP),一种沉默调节蛋白3(SIRT3)的特异性抑制剂,来阻断SIRT3/帕金通路。通过免疫组织化学评估软骨切片中的线粒体自噬。发现IL-1β通过抑制SIRT3表达和线粒体自噬诱导软骨细胞凋亡。此外,炎性损伤降低了线粒体膜电位并促进了细胞内活性氧(ROS)的产生,导致线粒体分裂增加、线粒体融合抑制以及随之而来的线粒体损伤。相比之下,MA-5处理通过上调线粒体自噬、维持线粒体膜电位和减少线粒体凋亡来抑制过量ROS的产生。在用3-TYP化学阻断SIRT3后,帕金相关的线粒体自噬也受到抑制,而MA-5预处理软骨细胞可防止这种作用,从而表明SIRT3在帕金的上游。总体而言,发现MA-5可增强SIRT3的活性,促进帕金依赖性线粒体自噬,消除软骨细胞中去极化/受损的线粒体,并保护软骨细胞。总之,MA-5通过上调SIRT3/帕金相关的自噬信号通路抑制IL-1β诱导的氧化应激并保护软骨细胞。